Nuo Therapeutics, Inc.: Form 10-Q/A for the period ended Jun 30, 2022
Filed with the SEC on Aug 10, 2022 and accepted by EDGAR at Aug 10, 2022, 17:28 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $0 | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $0 | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2022-04-01 to 2022-06-30 | $0 | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2022-01-01 to 2022-06-30 | $0 | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2022-04-01 to 2022-06-30 | $0 | us-gaap:GrossProfit |
| Gross profit | 6 months2022-01-01 to 2022-06-30 | $0 | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2022-04-01 to 2022-06-30 | $923.7k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2022-01-01 to 2022-06-30 | $1.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$923.7k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2022-04-01 to 2022-06-30 | −$924.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | −$1.3m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | −$1.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $51.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-06-30 | $3.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $3.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $4.3m | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $464.8k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $761.1k | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-06-30 | $3.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-22-019741. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.